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Recent reports have suggested a reproducible association between the rs11121615 SNP, located within 
an intron of the castor zinc finger 1 (CASZ1) gene, and varicose veins. This study aimed to determine 
if this variant is also differentially associated with the various clinical classifications of chronic venous 
disease (CVD). The rs11121615 SNP was genotyped in two independent cohorts from New Zealand 
(n = 1876 controls /1606 CVD cases) and the Netherlands (n = 1626/2966). Participants were clinically 
assessed using well-established CVD criteria. The association between the rs11121615 C-allele and 
varicose veins was validated in both cohorts. This was strongest in those with higher clinical severity 
classes and was not significant in those with non-varicose vein CVD. Functional analysis of the 
rs11121615 variant demonstrated that the risk allele was associated with increased enhancer activity. 
This study demonstrates that the CASZ1 gene associated C-allele of rs11121615 has a significant, 
reproducible, association with CVD (CEAP C ≥ 2 meta-odds ratio 1.31, 95% CI 1.27–1.34, P = 1 × 10−98, 
PHet = 0.25), but not with non-varicose vein (CEAP C1, telangiectasia or reticular veins) forms of venous 
disease. The effect size of this association therefore appears to be susceptible to influence by phenotypic 
heterogeneity, particularly if a cohort includes a large number of cases with lower severity CVD.
Chronic venous disease is common1 and is associated with a significant socioeconomic burden2, account-
ing for an estimated 1–2% of total health budget costs in Western Europe and the United States of America3. 
Family-based studies suggest that CVD has a strong genetic risk component4–6. Although a large number of 
candidate gene-based studies have been previously undertaken, these have failed to produce robust genetic asso-
ciations7. In recent years several genome-wide association studies (GWAS) have been conducted with a specific 
focus on varicose veins of the lower limbs. The first of these was conducted by 23andMe, examining European 
participants with self-declared varicose veins. This work was presented in poster form at the 64th Annual Meeting 
of the American Society of Human Genetics in 20148. This was followed by a GWAS examining more clinically 
verified cohorts of German participants9. Interestingly, there appeared to be little overlap between the results of 
these two GWAS. Very recently Shadrina and colleagues performed a validation of the top hits from both of these 
two GWAS, using two independent cohorts from Russia and the United Kingdom (UK Biobank)10. By far the 
strongest association, both in terms of effect size and statistical power, was with rs11121615, initially identified 
in the 23andMe study. This single nucleotide polymorphism (SNP) is located within an intron of the castor zinc 
finger 1 (CASZ1) gene however, to date, the functional consequence of this variant is unclear.
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We therefore undertook a validation study, in two independent cohorts from New Zealand (NZ) and the 
Netherlands (NL), to compare the association of this risk variant with different clinical classifications of venous 
disease. In addition, we performed functional analyses to determine the potential biological mechanism(s) 
through which the risk allele may be able to influence disease pathobiology.
Results
The demographics of the NZ and NL cohorts are shown in Table 1. The proportion of participants with CEAP C1 
disease reflected the differing designs of the two studies (NZ: selected cases referred for clinical venous assess-
ment, NL: a population-based cohort study). Accordingly, over half (57.5%) of the NL case cohort were in the 
CEAP C1 group while only 6% of the NZ cases had this clinical classification.
The association between rs11121615 and chronic venous disease. The rs11121615 SNP was in 
Hardy-Weinberg equilibrium in both the NZ (cases P = 0.86 and controls P = 0.10) and NL (cases P = 0.22 and 
controls = 0.07) cohorts.
The rs11121615 minor allele frequencies (MAF) for both cohorts are summarized in Figs 1 and 2. The fre-
quency of the minor C-allele was similar in the control cohorts from both NZ and NL (MAF 0.30 and 0.32 respec-
tively, P = 0.15). There was no statistical difference in the allele frequencies between controls and case participants 
with CEAP C1 venous disease in either study.
In both cohorts, those with varicose veins (CEAP ≥ C2 or self-declared but visually verified varicose veins) 
had a higher C-allele frequency than either controls or participants with CEAP C1. In the NL cohort, CEAP C1 
participants had a significantly (P < 0.0008) lower C-allele frequency than those with a CEAP ≥ C2 (Fig. 2). Given 
that CEAP C1 classified venous alterations are not considered to be varicose veins11, we then excluded such indi-
viduals from the subsequent association analysis. The unadjusted odds ratio for the C-allele being associated with 
varicose veins (CEAP ≥ C2 or visually verified varicose veins) were 1.30 (95% CI 1.17–1.44, P = 5.5 × 10−7) and 
1.18 (1.06–1.32, P = 2.5 × 10−3) in the NZ and NL cohorts (Figs 1 and 2 respectively and Supplementary Table 2). 
These associations remained significant after including age and sex as covariates (1.27, 1.14–1.42, P = 9.9 × 10−6 
and 1.17, 1.04–1.31, P = 0.01 respectively).
A meta-analysis was performed using the major T-allele as the reference and minor C-allele as the risk variant. 
The odds ratios from all contributing cohorts were adjusted for age and sex. The NZ and NL C-allele associations 
in those with varicose veins and more advanced CVD (by excluding those with CEAP C1) were analyzed in a 
Controls, 
CEAP C0
Self-declared 
VV CEAP C1 CEAP C2 CEAP C3 CEAP C4 CEAP C5-6
Varicose veins 
CEAP ≥ C2
New Zealand, n 1876 564 97 535 60 202 148 1509
Age 68.8 (7.6) 67.7 (9.5) 71.2 (10.5) 60.4 (14.7) 63.3 (12.0) 60.8 (11.8) 63.0 (12.6) 64.3 (12.3)
sex (% male) 64.6 50.0 56.4 38.7 46.6 55.3 56.7 47.7
The Netherlands, n 1626 — 1704 925 268 62 7 1262
age 68.4 (9.6) — 69.4 (9.8) 71.9 (9.7) 75.3 (9.1) 76.0 (10.9) 67.5 (14.1) 72.8 (9.8)
sex (% male) 53.4 — 34.2 39.7 38.4 40.3 57.4 39.5
Table 1. Demographics of the New Zealand and Netherlands cohorts divided by chronic venous disease 
clinical classification. Participants were characterised using the clinical classification matrix of the CEAP 
chronic venous disease criteria, except a group of self-declared NZ participants, who were visually inspected 
to confirm varicose veins and exclude those with CEAP C1. CEAP clinical classifications; (C0) No evidence of 
venous disease, (C1) telangiectasia or reticular veins, (C2) uncomplicated varicose veins, (C3) edema, (C4) Skin 
changes ascribed to venous disease (pigmentation or eczema, lipodermatosclerosis), (C5) healed or (C6) active 
venous ulcer. Age is represented as mean (standard deviation).
Figure 1. rs11121615 C-allele (CASZ1) association with chronic venous disease in the New Zealand cohort. 
*The ‘Any VV’ group includes those with clinically classified (CEAP ≥ C2) and the self-declared (but visually 
verified) varicose veins.
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fixed effect model meta-analysis with the previously reported 23andMe, Russian and United Kingdom associ-
ations. The resulting odds ratio was highly statistically significant (Fig. 3, odds ratio 1.20, 95% CI 1.18–1.22, 
P = 1.5 × 10−90). Despite consistent directions of effect across all cohorts there was significant heterogeneity in the 
fixed effect model (I2 95.8, PHet < 1 × 10−8). This was driven primarily by the inclusion of the 23andMe cohort, 
with the meta odds ratio rising to 1.31 (95% CI 1.27–1.34, P = 9.0 × 10−99) and no significant heterogeneity in 
effect (I2 27.6, PHet = 0.25) when this cohort was excluded. In a random effects model the rs11121615 C-allele 
had an odds ratio for association with varicose veins of 1.22 (95%CI 1.09–1.36, P = 5.2 × 10−4) which increased 
to 1.28 (95%CI 1.22–1.35, P = 4.5 × 10−22) when the 23andMe cohort was excluded.
Because of the well clinically phenotyped nature of the NZ and NL cohorts a further analysis was conducted 
to determine if the rs111211615 C-allele showed any further stratified association with the clinical classification 
of CVD. In both cohorts the highest C-allele frequency was observed in those with CEAP C4-6. In the NZ cohort 
there was a significant difference between those with either self-declared varicose veins or varicose veins with or 
without edema (CEAP C3 or C2 respectively) and those with CEAP ≥ C4 (Fig. 1, C-allele frequency 0.35 versus 
0.40 respectively, P = 0.02).
Rs11121615 functional analysis. The ability of rs11121615 to alter regulatory element activity was exam-
ined using publicly available ENCODE and Roadmap Epigenomics project data. In NHEK (normal human epi-
dermal keratinocytes), the rs11121615 DNA region had a H3K27ac and H3K4me1 peak, DNase I hypersensitivity 
sites and was annotated as an enhancer by ChromHMM (Fig. 4A). It had documented enhancer functions in mul-
tiple other primary cell types (epithelial, brain, digestive, muscle, heart, lung, liver and pancreas) (Supplementary 
Table 2). Further, rs1121615 resides in a region that is conserved in vertebrates (Fig. 4A). Rs11121615 is predicted 
to alter the binding motif of the mouse zinc-finger transcription factors Zfp128, Zic1 and Zic2 (Supplementary 
Fig. 1), indicating it might affect gene regulation by altering the binding affinity of transcription factors.
To experimentally confirm whether the rs11121615 DNA region harbors enhancer activity, and to assess 
whether the SNP alters its activity, a luciferase assay was performed in HEK293 cells. The major (T) allele did not 
harbour enhancer activity, while the minor (C) allele showed significant activity (Fig. 4B). This data suggested 
that the risk allele of rs11121615 increases enhancer activity, and gives insight into the mechanism through which 
it could influence gene expression.
Whether rs11121615 regulates the expression of CASZ1 and/or of genes further away was assessed using 
publicly available chromatin interaction (Hi-C) and expression quantitative trait loci (eQTL) data. Hi-C data in 
several cell lines indicates that rs11121615 is located within a topologically associated domain (TAD) spanning 
from DFFA/PEX14 at the upstream boundary to TARDBP at the downstream boundary (Fig. 4C). The TAD 
boundaries were similar in all cell types for which Hi-C data is available (data not shown). Genes within the 
Figure 2. rs11121615 C-allele (CASZ1) association with chronic venous disease in the Netherlands study.
Figure 3. rs11121615 C-allele (CASZ1) meta-analysis association with chronic venous disease. Both the NZ 
and NL cohorts consisted of chronic venous disease cases with CEAP ≥ C2. Case control status in the 23andMe 
cohort was self-declared (unverified). The Russian cases and controls were confirmed by clinical examination 
(CEAP ≥ C2), while the UK Biobank case status was electronically extracted from ICD10 clinical modification 
codes (I83; varicose veins of the lower extremity). Results from all cohorts were adjusted for age and sex.
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domain included CASZ1 and C1orf127 (an uncharacterized protein-coding gene) (Fig. 4C). Genes near the TAD 
boundaries, such as DFFA (DNA fragmentation factor subunit alpha), PEX14 (a peroxisome membrane protein) 
and TARDBP (a DNA and RNA-binding protein that regulates transcription and splicing), are ‘housekeeping’ 
type of genes and have no known specific function in vascular-related cell types. Given that regulatory elements 
typically confine their activity within TADs, and TAD boundaries are enriched for housekeeping genes12,13, it is 
likely that the rs11121615-containing enhancer regulates the expression of CASZ1 and/or C1orf127, and not of 
DFFA/PEX14 or TARDBP.
eQTL data from GTEx (Genotype-Tissue Expression) and ASAP (Advanced Study of Aortic Pathology) were 
explored to identify eQTLs for rs1112161514,15. In GTEx, no significant eQTL for rs11121615 were present, while 
the ASAP study had two significant eQTLs for CTNNBIP1 (P = 0.00082) and TARDBP (P = 0.013) in heart tissue. 
These genes are not located within the TAD however, and it is therefore unclear whether rs11121615 might reg-
ulate the expression of these genes.
Figure 4. rs11121615 affects enhancer activity within a topologically associated domain (TAD) containing 
CASZ1. (A) UCSC snapshot showing the following tracks: UCSC genes, 100 vertebrates basewise conservation 
by PhyloP, ENCODE layered ChIP-Seq data for H3K27ac and H3K4me1 from seven cell lines (NHEK cells 
in purple), ENCODE DNase I hypersensitivity data, and 15-state chromatin state Segmentation by HMM 
(ChromHMM) for nine cell lines. hg19 chromosome 1 coordinates are shown. (B) Allele-specific enhancer 
activity for rs11121615 was assessed using a luciferase reporter assay in HEK293 cells. The rs11121615 T variant 
(major allele) did not harbour enhancer activity whereas the C variant (minor allele) did. The average of five 
biological replicates+/− the standard error of the mean is shown. Statistical significance was determined by 
a one-way ANOVA followed by a Tukey’s multiple comparisons test (*P < 0.0001). (C) Hi-C contact map in 
NHEK cells (normal human epidermal keratinocyte) at chr1:10140000-11450000 (hg19), obtained from the 
3D genome browser (http://www.3dgenome.org). TADs, calculated using the directional bias method13, are 
indicated by alternating orange and blue bars. NCBI reference genes are annotated below.
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Discussion
This study validated by far the strongest previously reported genetic association with CVD8,10. Located within 
intron 1 of the CASZ1 gene, the minor C-allele of rs11121615, had a significant positive association with CVD 
in all five of the independent populations examined to date. Of note, however, the fixed effect model suggested 
significant heterogeneity of effect, with the outlier population appearing to be the 23andMe cohort.
When considering results of case control genetic association studies, it is important to consider the quality 
of both case and control phenotyping. The 23andMe study, which was the first to report the CASZ1 association, 
utilized self-declared case status, which does not inform the clinical severity of disease and is potentially prone to 
bias based on an individual’s perception of what constitutes a varicose vein. For example, in the 23andMe cohort 
the case prevalence in females was almost three times higher than males, an observation which does not match 
that reported in well-designed epidemiological studies1. Nor were cases and controls well matched for age in 
the study. Offsetting these issues was the very large sample size (over 20,000 cases) that was examined. In con-
trast, the UK Biobank dataset has over 10,000 varicose vein cases, with the advantage of improved phenotyping 
via electronic extraction of International Classification of Disease (ICD10) codes (I83; varicose veins of lower 
extremities), however, there was no clinical sub-classification of those with CVD. The Russian cohort reported by 
Shadrina and colleagues had cases confirmed by clinical examination and duplex ultrasound with all having visi-
ble varicose veins and reflux in either the great or small saphenous vein. The vast majority of this cohort (n = 590, 
83.2%) had CEAP C2-3 classified disease.
In order to determine the possible impact of such self-declared case designation, we included a group of 
NZ participants who had self-reported as having varicose veins on a research recruitment health questionnaire 
(albeit with a degree of verification via visual observation of the patient’s lower limbs by a vascular sonographer). 
Encouragingly, these participants showed a similar varicose vein risk association for the rs11121615 C-allele to 
that of patients with CEAP C2-3 in both the NZ and Dutch studies, suggesting that, at least for this variant, the 
self-declared phenotype represents a valid association with varicose veins. Of note, however, those classified as 
having CEAP C1 venous disease did not show an association with the rs11121615 C-allele in either of the cohorts 
in this study, with allele frequencies being strikingly similar to venous disease-free controls. Given that CEAP 
C1 classified venous alterations are not considered to be varicose veins11, the rs11121615 association appears to 
represent a varicose vein specific effect. Moreover, this suggests that inclusion of CEAP C1 individuals in a case 
cohort, for example when case designation is collected via an unverified self-declared mechanism, would influ-
ence the resulting analysis towards the null hypothesis of no association.
We suggest that this is the possible explanation for the lower effect size observed in the 23andMe cohort. 
While the meta-analysis indicated a C-allele odds ratio of 1.2 when all cohorts were included, our data suggests 
that the association is more likely to be in the order of 1.3 for uncomplicated varicose veins (CEAP C2) and poten-
tially as high as 1.5 for CVD with skin changes and venous ulcers (CEAP C4-6).
Rs11121615 is located in intron 1 of the CASZ1 gene, and thus does not directly alter protein function. Our 
bioinformatic analysis of the region harboring rs11121615 suggested potential enhancer functions in multiple 
cell types. Importantly, we demonstrated that the varicose vein associated C-allele of this SNP confers a signifi-
cant increase in enhancer activity. Chromatin interaction analysis suggested that CASZ1 is a likely target of this 
enhancer regulation. CASZ1 is expressed in human endothelial cells and drives the expression of Epidermal 
Growth Factor Like-Domain 7 (EGFL7), which in turn drives the expression of the RhoA gene. RhoA mediates 
NF-κB dependent gene expression, including VEGFR2, and thereby stimulates angiogenesis and vascular assem-
bly16. Taken together, our data supports the proposition that rs11121615 is a causal variant influencing risk of 
developing varicose veins via alterations in the transcription factor CASZ1, an upstream regulator of vascular 
structure.
The observation that the rs11121615 C-allele is more strongly associated with more severe forms of CVD, 
particularly venous ulceration, needs further investigation. If this proves to be the case, this variant may have 
utility identifying those individuals with varicose veins who are at greater risk of progression to more severe, 
higher classes of CVD.
Methods
Participants. All New Zealand participants were recruited from the Otago-Southland region of New 
Zealand’s South Island. Participants were either part of the Otago Vascular Genetics Research (OVGR) cohort17 
or were patients referred for superficial venous disease assessment. OVGR participants completed a self-ad-
ministered health questionnaire which included the question “Have you ever had, or been treated, for varicose 
veins”. All participants attended the recruitment facility in the local hospital, at which time the questionnaire 
was reviewed by experienced recruitment staff. Visual inspection of the limbs of those indicating that they had 
varicose veins was performed by an experienced vascular sonographer. Those with only telangiectasia or retic-
ular veins were recoded as not having significant varicose veins. Patients referred for superficial venous disease 
assessment to the Otago Vascular Diagnostics Laboratory were also recruited. These patients underwent a formal 
assessment for lower limb superficial chronic venous disease, including full ultrasound examination, and were 
classified using the clinical classification matrix of the clinical, etiological, anatomical and pathological (CEAP) 
chronic venous disorders criteria11. For bilateral disease the class of the most severely affected limb was recorded. 
In brief, CEAP C0, no visible or palpable signs of venous disease; C1, telangiectasia or reticular veins; C2, vari-
cose veins (VV), distinguished from reticular veins by a diameter of greater than or equal to 3 mm; C3, edema of 
venous origin; C4, skin hyperpigmentation or lipodermatosclerosis; C5, healed venous ulcer; C6, active venous 
ulceration.
All participants from the Netherlands (NL) were part of the Rotterdam Study18, and were clinically assessed 
using the same CEAP classification as the NZ venous disease cohort.
6Scientific RepoRtS |         (2019) 9:14011  | https://doi.org/10.1038/s41598-019-50586-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
All participants gave written informed consent and all research was performed in accordance with relevant 
guidelines/ regulations. In New Zealand the study was approved by the Health and Disability Ethics Committee 
(New Zealand Ministry of Health), while in the Netherlands the Rotterdam study was approved by Erasmus 
Medical Center’s Medical Ethics Committee and by the review board of The Netherlands Ministry of Health, 
Welfare and Sports.
All participants had DNA extracted from an EDTA blood sample for genotyping. New Zealand samples were 
assessed using a Taqman assay (C_3092341_20, Thermofisher Scientific, MA, USA).
In the Rotterdam Study, DNA from whole blood was extracted following standard protocols19. Genome-wide 
SNP array data is available for the Rotterdam Study with details described by Hofman and colleagues19. SNP cov-
erage was further expanded by imputation using the MACH software (http://csg.sph.umich.edu/abecasis/mach/
index.html), with default parameters, and the 1000Genomes (GIANT Phase I version 3) as the reference panel. In 
total 30,072,738 markers were genotyped and/or imputed. From this data we extracted best guess genotypes for 
the rs11121615 SNP using GCTA20 with parameter defaults. The imputation quality score for this SNP was 0.76.
Genetic association statistical analysis. The SNP-disease associations in the NZ and NL cohorts were 
determined using PLINK (http://pngu.mgh.harvard.edu/purcell/plink/)21. The Fisher’s exact test was used to 
test allelic associations. Logistic regression was used to determine interactions with covariates (age and sex). 
Meta-analysis was performed using fixed and random-effects modelling using the Comprehensive Meta-Analysis 
software package, version 3 (www.meta-analysis.com/). Effects sizes were reported as odds ratios (OR) and 95% 
confidence intervals. Inter-study heterogeneity was measured using the I2 statistic.
Functional studies. Luciferase assay. Enhancer activity of the region spanning rs11121615 was assessed 
using a luciferase reporter assay in the human embryonic kidney cell line HEK293. A 2 kb region spanning 
rs11121615 was amplified from the 1000 Genomes sample HG00112 (heterozygous for rs11121615)22, cloned 
into the pCR®8/GW/TOPO entry vector and recombined into pGL4.23-GW (Addgene, MA, USA) using the 
Gateway® system (LR Clonase® Enzyme mix, Invitrogen, Thermofisher Scientific, MA, USA). Primers used 
to amplify the cloned regions can be found in Supplementary Table 4. The construct obtained was Sanger 
sequenced and contained the minor allele of rs11121615 (T). Site-directed mutagenesis (SDM) was carried out 
obtain a construct containing the major allele of rs11121615 (C). The SDM protocol used was adapted from 
the QuikChange II site-directed mutagenesis protocol (Agilent Technologies, CA, USA). PCR was performed 
using PfuUltra High-Fidelity DNA Polymerase (Agilent Technologies) using the primers listed in Supplementary 
Table 4. Parental plasmid DNA was digested with DpnI (Agilent Technologies) and mutagenized plasmids were 
then transformed into E. coli TOP10 chemically competent cells. SDM was confirmed using Sanger sequenc-
ing. All plasmids used for transfections were isolated using the NucleoBond Xtra Midi endotoxin-free kit 
(Macherey-Nagel GmbH, Germany).
One day prior to transfection, HEK293 cells were seeded at 8 × 103 cells per well in a 96-well plate in 200 μL 
DMEM supplemented with 10% fetal bovine serum (Moregate, NZ). Transfections were carried out using 
Lipofectamine 3000 (Invitrogen) with 100 ng of each pGL4.23 construct and 4 or 20 ng of pRL-TK (Renilla; 
Promega, WI, USA) per well. Luminescence was measured 48 hours post-transfection using the Dual Glo 
Luciferase Assay System (Promega), on a Perkin Elmer Victor X4 plate reader. Firefly luciferase was normalised 
to that of Renilla and expressed relative to pGL4.23 lacking a gateway cassette.
ChIP-seq, DNase I, Hi-C, eQTL data, and computational prediction of transcription factor binding motif affin-
ity. Histone modification ChIP-seq, DNase I hypersensitivity and 15-state ChromHMM data was obtained from 
the ENCODE23 and Roadmap Epigenomics24 projects through the UCSC genome browser (https://genome.ucsc.
edu/) and the 3DSNP database (http://cbportal.org/3dsnp/). Previously described Hi-C data in NHEK cells was 
obtained using the 3D genome browser (http://www.3dgenome.org). eQTL data were obtained from GTEx and 
ASAP. RegulomeDB (http://www.regulomedb.org) was used to predict alterations in transcription factor binding 
motifs.
Data Availability
The datasets generated during the current study are available from the corresponding author on reasonable re-
quest.
References
 1. Evans, C. J., Fowkes, F. G., Ruckley, C. V. & Lee, A. J. Prevalence of varicose veins and chronic venous insufficiency in men and 
women in the general population: Edinburgh Vein Study. J Epidemiol Community Health 53, 149–153 (1999).
 2. Onida, S. & Davies, A. H. Predicted burden of venous disease. Phlebology 31, 74–79 (2016).
 3. Rabe, E. & Pannier, F. Societal costs of chronic venous disease in CEAP C4, C5, C6 disease. Phlebology 25(1), 64–67 (2010).
 4. Ahti, T. M., Makivaara, L. A., Luukkaala, T., Hakama, M. & Laurikka, J. O. Effect of family history on the incidence of varicose veins: 
a population-based follow-up study in Finland. Angiology 60, 487–491 (2009).
 5. Brinsuk, M., Tank, J., Luft, F. C., Busjahn, A. & Jordan, J. Heritability of venous function in humans. Arterioscler Thromb Vasc Biol 
24, 207–211 (2004).
 6. Cornu-Thenard, A., Boivin, P., Baud, J. M., De Vincenzi, I. & Carpentier, P. H. Importance of the familial factor in varicose disease. 
Clinical study of 134 families. J Dermatol Surg Oncol 20, 318–326 (1994).
 7. Krysa, J., Jones, G. T. & van Rij, A. M. Evidence for a genetic role in varicose veins and chronic venous insufficiency. Phlebology 27, 
329–335 (2012).
 8. Bell, R. K. et al. In The 64th Annual Meeting of The American Society of Human Genetics. Paper no. 2082M, p. 2487. https://
blog.23andme.com/wp-content/uploads/2014/10/Bell_ASHG2014_varicose.pdf (last accessed 4 April 2019).
 9. Ellinghaus, E. et al. Genome-wide association analysis for chronic venous disease identifies EFEMP1 and KCNH8 as susceptibility 
loci. Sci Rep 7, 45652 (2017).
7Scientific RepoRtS |         (2019) 9:14011  | https://doi.org/10.1038/s41598-019-50586-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
 10. Shadrina, A. et al. Polymorphisms of genes involved in inflammation and blood vessel development influence the risk of varicose 
veins. Clin Genet 94, 191–199 (2018).
 11. Rabe, E. & Pannier, F. Clinical, aetiological, anatomical and pathological classification (CEAP): gold standard and limits. Phlebology 
27(1), 114–118 (2012).
 12. Symmons, O. et al. Functional and topological characteristics of mammalian regulatory domains. Genome Res 24, 390–400 (2014).
 13. Dixon, J. R. et al. Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature 485, 376–380 
(2012).
 14. Folkersen, L. et al. Association of genetic risk variants with expression of proximal genes identifies novel susceptibility genes for 
cardiovascular disease. Circ Cardiovasc Genet 3, 365–373 (2010).
 15. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet 45, 580–585 (2013).
 16. Charpentier, M. S. et al. CASZ1 promotes vascular assembly and morphogenesis through the direct regulation of an EGFL7/RhoA-
mediated pathway. Dev Cell 25, 132–143 (2013).
 17. Jones, G. T. et al. Comparison of three targeted approaches to screening for abdominal aortic aneurysm based on cardiovascular risk. 
Br J Surg 103, 1139–1146 (2016).
 18. Ikram, M. A. et al. The Rotterdam Study: 2018 update on objectives, design and main results. Eur J Epidemiol 32, 807–850 (2017).
 19. Hofman, A. et al. The Rotterdam Study: 2016 objectives and design update. Eur J Epidemiol 30, 661–708 (2015).
 20. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet 88, 
76–82 (2011).
 21. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81, 
559–575 (2007).
 22. Genomes Project Consortium. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).
 23. Rosenbloom, K. R. et al. ENCODE data in the UCSC Genome Browser: year 5 update. Nucleic Acids Res 41, D56–63 (2013).
 24. Roadmap Epigenomics Consortium. et al. Integrative analysis of 111 reference human epigenomes. Nature 518, 317–330 (2015).
Acknowledgements
The authors wish to thank the study participants, without whom this work could not have been performed. This 
study was supported by the Health Research Council of New Zealand and H.S. and J.C. Anderson Charitable Trusts 
(GTJ). Genetic analysis was supported by infrastructure from Genomics Aotearoa (www.genomics-aotearoa.org.nz). 
HEK293 cells were kindly provided by Dr. Heather Cunliffe (Department of Pathology, University of Otago, Dunedin).
Author Contributions
G.J. designed the study, performed the genetic analysis and drafted the manuscript. J.M., C.L.S. and J.H. 
performed the functional analysis. L.P., T.N. and M.D.M. were responsible for the Netherlands data acquisition, 
interpretation. V.P. was performed the New Zealand study genotyping. J.K. and A.v.R. were involved with New 
Zealand clinical data acquisition. All authors reviewed the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-50586-2.
Competing Interests: The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
